- In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point. Alkorta, M., Giménez, M.J., Vicente, D., Aguilar, L., Pérez-Trallero, E. Int. J. Antimicrob. Agents (2005)